- Home
- CGO vs VANI Comparison
CGO vs VANI Comparison
Compare CGO & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | VANI |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.3M | 95.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CGO | VANI |
|---|---|---|
| Price | $12.52 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 29.0K | ★ 302.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.26 | $0.92 |
| 52 Week High | $12.79 | $1.92 |
Technical Indicators
Market Signals| Indicator | CGO | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 65.35 | 60.54 |
| Support Level | $11.37 | $1.19 |
| Resistance Level | N/A | $1.57 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 92.01 | 66.35 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.